I'm writing a feature-length piece on the use of Spravato (esketamine) for treatment-resistant depression. I'm interested in talking to researchers, physicians/psychiatrists/therapists who prescribe it (especially if you have insight into their responses good and bad and neutral), and especially interested in finding a few individuals who had varied experiences using it (can use pseudonym). Researchers who worked on its clinical trial or have any insight into how they were done (were they fast tracked? etc) or studied it in any way for its side effects and/or benefits, and also anyone with insight into the recent FDA warning on the compounded esketamine dangers (this will be a minor part of the story).

I was part of early esketamine (Spravato(r)) trials and later followed its rollout in clinics. Esketamine was given breakthrough/priority review because it produces rapid antidepressant effects (hours-days) in many people with treatment-resistant depression — an important advance when standard meds take weeks. The pivotal TRANSFORM/SUSTAIN program showed faster symptom reduction vs placebo, but effects and durability vary. Main clinical realities I hear from prescribers (good / mixed / bad): Dr. "Maya" (positive): Many patients show dramatic mood lift within 24-72 hours. For suicidality or severe anhedonia, she called it "life-saving" when other options failed. Follow-up care and psychotherapy made benefits stick. Dr. "Alan" (neutral): He sees a 40-60% response rate but notes relapse is common if maintenance is stopped. Cost, travel, and the REMS-style monitoring make it impractical for some. Dr. "Priya" (concerned): She reports dissociation, sedation, transient BP spikes, and rare respiratory events — requiring on-site monitoring for 2+ hours and trained staff. Some patients dislike the subjective effects and discontinue. Safety/regulatory notes: Spravato carries boxed warnings (sedation, dissociation, respiratory depression, abuse) and is limited to certified clinics with monitoring; long-term effects are still under study. The FDA has repeatedly warned about compounded (non-FDA) ketamine/nasal preparations, citing safety, variability, and at-home use risks — an important contrast to supervised Spravato administration. Practical tips for your reporting: Emphasize rapid onset vs uncertain durability. Note systemic barriers: REMS logistics, cost, access. Include patient voices (use pseudonyms) showing the range: "transformative," "helpful but temporary," and "too intense/side effects." Cover the FDA's warnings on compounded ketamine as a safety caveat. If you want, I can draft three short anonymized clinician interviews (quotes), plus a 200-300 word explainer box on trial design and regulatory timeline with citations.

In my psychiatry practice, Spravato (esketamine) is a vital tool for a specific group of patients with treatment-resistant depression, but it is not a simple fix; it is a significant medical procedure. Its greatest strength is speed. For a patient who has failed multiple other treatments, seeing a meaningful reduction in depressive symptoms or suicidal thoughts within 24 hours can be absolutely remarkable. It offers a path forward when many feel they've hit a wall. The "bad" and "neutral" responses are really two sides of the same coin: the intense, in-office experience. Patients must be monitored by a healthcare professional for at least two hours after every dose. This is because we expect side effects like dissociation—a "drunk" or "out-of-body" feeling—as well as sedation and a significant, temporary spike in blood pressure. We monitor blood pressure before, during, and after, and patients cannot drive until the next day. From a clinical standpoint, it's also important to understand that this is not a standalone treatment. It must be administered in conjunction with an oral antidepressant. The logistical burden is high for both the patient and the clinic, as it's a Schedule 2 controlled drug requiring specialist supervision. The results vary; some patients have a life-changing response, while others find the side effects or the logistics too difficult to manage. It's a high-resource treatment, but for the right person, it provides an option where none existed before.

I'm Dr. Michael Chichak, a general practitioner with significant expertise in mental health treatment and managing patients with complex, treatment-resistant conditions. The short story on Spravato is that doctors view it as a powerful but complicated tool. We love it because it acts super fast on the brain's NMDA receptor. It can lift severe depression even when other medications have failed. Consequently, for people struggling severely with treatment-resistant depression (TRD), that quick relief is huge. However, the major pain point for clinics is the mandatory safety rules, REMS. This system forces us to keep patients for two hours of on-site monitoring after they take the drug. While necessary for safety, it's logistically a real hassle, slowing things down and limiting how many people we can help. Patient experience is varied. Some feel immediate, dramatic improvement, which is the best-case scenario. Conversely, others must be prepared for the expected side effects, like feeling dizzy or disconnected during the two hours. Furthermore, it's not a quick cure; many people need ongoing treatments to keep the depression from coming back. It's a serious commitment, but it offers hope.

I served as Director of Psychiatry at an interventional psychiatry clinic where I provided ketamine infusions and Transcranial Magnetic Stimulation for patients with treatment-resistant depression. This experience gave me direct insight into ketamine-based treatments for this patient population. I would be happy to discuss my clinical perspective on treating patients with these interventional approaches. Please feel free to reach out to arrange a conversation about how this relates to your piece.

I regularly evaluate and treat patients with treatment-resistant depression using Spravato (esketamine). In clinical practice, the range of responses is broader than many expect. Some patients experience a noticeable lift in mood within hours of the first or second session, especially those who have failed multiple antidepressants but still retain some reactivity to treatment. Others require several weeks before any meaningful shift occurs. There is also a group whose improvement is modest or temporary, and a smaller subset who ultimately discontinue because they find the dissociative effects uncomfortable or not aligned with what they were expecting. Seeing all three patterns; positive, neutral, and minimal response, has shaped how we set expectations before treatment begins. We follow structured safety protocols during each session: blood pressure monitoring, supervision during the dissociative phase, and screening for factors that may complicate treatment, such as uncontrolled anxiety or substance use. The distinction between therapeutic dissociation and distressing dissociation is something we pay close attention to, especially in the first few doses. The setting matters a great deal; patients who feel safe, prepared, and supported tend to tolerate the experience significantly better. On the research side, my understanding is that esketamine's approval involved expedited pathways due to the need for novel options for treatment-resistant depression, but the core trials still followed standard clinical-rigor requirements. The data showed clear benefit for a subset of patients, though not universally, which aligns with what we see in real-world practice. Regarding the recent FDA warning on compounded esketamine, the concerns center on variability in potency, formulation, and lack of required monitoring. In clinical settings, Spravato's standardized dosing and strict REMS requirements are part of what makes it a safer, more predictable option. Patients sometimes assume compounded formulations are equivalent, but the consistency and safety oversight are not the same, which is why the FDA flagged it.